Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp has demonstrated strong growth potential, particularly within its plasma and hospital segments, with the hemostasis management business experiencing a remarkable 27% increase in the U.S. Additionally, the company's plasma growth, excluding CSL, is primarily driven by market share gains among key large customers and advantageous pricing associated with recent product upgrades. Overall, the plasma business has shown double-digit growth and has exceeded expectations, highlighting its robust demand and favorable market dynamics.

Haemonetics Corp reported a significant decline in total revenue, with a notable drop of 21.7% attributed to divestitures, despite showing a modest organic growth of 4.4%. The company’s FY/26 guidance indicates an expected total reported revenue decline of 3% to 6%, although projected organic growth remains between 6% to 9%, underscoring concerns over its reliance on divestures for overall performance. Additionally, the anticipated adjusted operating margin of 26% to 27% and a forecast of non-GAAP EPS between $4.70 and $5.00 may not completely mitigate investor concerns stemming from the overall revenue contraction.